{
    "ticker": "LNTH",
    "name": "Lantheus Holdings, Inc.",
    "description": "Lantheus Holdings, Inc. is a global leader in the development and commercialization of innovative diagnostic and therapeutic agents. Founded in 1956 and headquartered in North Billerica, Massachusetts, Lantheus specializes in medical imaging and radiopharmaceuticals, focusing on improving patient care through advanced imaging technologies. The company's flagship product, Pylarify, is a PET imaging agent used in the detection of prostate cancer, showcasing Lantheus's commitment to addressing critical medical needs in oncology. Lantheus is dedicated to advancing the field of nuclear medicine by investing in research and development, resulting in a robust pipeline of diagnostic and therapeutic products aimed at enhancing patient outcomes. The company's mission is to provide healthcare professionals with the tools they need to make informed decisions, ultimately leading to better patient management and treatment strategies. Lantheus is also exploring new frontiers in precision medicine by leveraging its expertise in biomarker imaging to develop targeted therapies. The company's commitment to innovation, quality, and patient-centered solutions has positioned it as a trusted partner in the healthcare community.",
    "industry": [
        "Healthcare",
        "Pharmaceuticals"
    ],
    "headquarters": "North Billerica, Massachusetts, USA",
    "founded": "1956",
    "website": "https://www.lantheus.com",
    "ceo": "Jorge R. Gomez",
    "social_media": {
        "twitter": "https://twitter.com/lantheus",
        "linkedin": "https://www.linkedin.com/company/lantheus/"
    },
    "investor_relations": "https://investors.lantheus.com",
    "key_executives": [
        {
            "name": "Jorge R. Gomez",
            "position": "CEO"
        },
        {
            "name": "Katherine A. N. H. H. DeRosa",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Imaging",
            "products": [
                "Pylarify",
                "Definity"
            ]
        },
        {
            "category": "Therapeutics",
            "products": [
                "I-123 MIBG"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lantheus Holdings, Inc. | Innovative Diagnostic and Therapeutic Solutions",
        "meta_description": "Explore Lantheus Holdings, Inc., a leader in medical imaging and radiopharmaceuticals. Discover our innovative products and commitment to improving patient outcomes.",
        "keywords": [
            "Lantheus",
            "Medical Imaging",
            "Radiopharmaceuticals",
            "Oncology",
            "Pylarify",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What does Lantheus specialize in?",
            "answer": "Lantheus specializes in medical imaging and radiopharmaceuticals, focusing on diagnostic and therapeutic solutions."
        },
        {
            "question": "Who is the CEO of Lantheus?",
            "answer": "Jorge R. Gomez is the CEO of Lantheus Holdings, Inc."
        },
        {
            "question": "Where is Lantheus headquartered?",
            "answer": "Lantheus is headquartered in North Billerica, Massachusetts, USA."
        },
        {
            "question": "What are Lantheus's main products?",
            "answer": "Lantheus's main products include Pylarify and Definity."
        },
        {
            "question": "When was Lantheus founded?",
            "answer": "Lantheus was founded in 1956."
        }
    ],
    "competitors": [
        "PETV",
        "BMY",
        "ABT"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "AVEO"
    ]
}